U.S. General Anesthesia Drugs Market Summary

The U.S. general anesthesia drugs market size was valued at USD 1.72 billion in 2024 and is projected to grow at a CAGR of 2.82% from 2025 to 2030. This growth is supported by several factors, including the rising number of surgical procedures, continuous technological advancements in anesthesia administration, evolving regulatory frameworks, and significant shifts in healthcare practices. The American Society of Aesthetic Plastic Surgeons (ASPS) reported that 26.2 million surgical procedures were performed in the U.S. in 2022. Furthermore, data published by the National Library of Medicine highlighted that, in 2021, nearly nine major surgeries were conducted per 100 older adults, with more than one in seven Medicare beneficiaries undergoing a major surgery within five years. This reflects a substantial and increasing demand for reliable and effective general anesthesia drugs across the country.

The growing number of surgical procedures being carried out each year is the primary driver of market growth. The American Society of Anesthesiologists (ASA) attributes this trend to multiple factors such as an aging population, the higher prevalence of chronic and lifestyle-related diseases, and continuous advancements in surgical techniques. According to the CDC, individuals aged 65 years and older are particularly vulnerable to chronic conditions including cardiovascular disease, chronic obstructive pulmonary disease (COPD), diabetes, cancer, and neurological disorders. These conditions frequently require medical interventions involving major surgeries. Consequently, the demand for general anesthesia continues to grow, particularly in orthopedic, cardiovascular, neurological, and elective surgical procedures.

Key Market Trends & Insights

• In 2024, the propofol segment dominated the market with a share of 25.52% and is projected to record the fastest growth during the forecast period. Its dominance is attributed to its widespread use as the preferred agent for induction and maintenance of anesthesia due to its rapid onset and short recovery profile, which make it suitable for a wide range of surgical procedures.
• The intravenous (IV) segment also held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR of 3.03% during the forecast period. The reliability, efficiency, and convenience of IV administration make it the most preferred method in clinical practice, particularly for delivering drugs like propofol, ketamine, and thiopental. This dominance highlights the continued reliance on IV formulations for ensuring consistent anesthesia outcomes across surgical procedures.
• In terms of applications, the knee and hip replacement segment captured a significant revenue share in the U.S. general anesthesia drugs market in 2024. This trend is largely driven by the rising incidence of osteoarthritis and other degenerative joint disorders, which are leading to an increasing number of joint replacement surgeries. According to the Centers for Disease Control and Prevention (CDC), more than 32.5 million adults in the U.S. are affected by osteoarthritis, creating a large patient base requiring surgical intervention. This directly supports higher utilization of general anesthesia drugs in orthopedic procedures.
• Hospitals accounted for the largest revenue share of 67.05% in 2024, dominating the U.S. general anesthesia drugs market. Hospitals remain the primary centers for major surgeries and complex medical interventions requiring general anesthesia. According to the American Hospital Association (AHA), there are more than 6,000 hospitals operating in the United States, collectively handling millions of surgical cases annually. This concentration of surgeries within hospital settings reinforces their dominance in driving demand for anesthesia drugs.

Order a free sample PDF of the U.S. General Anesthesia Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 1.72 billion
• 2033 Projected Market Size: USD 2.03 billion
• CAGR (2025 - 2033): 2.82%

Key Companies & Market Share Insights

The U.S. market is dominated by several major pharmaceutical companies that collectively account for a significant market share. These leading players established themselves through extensive research and development efforts, resulting in the introduction of innovative treatment options. They also expanded their drug portfolios through strategic collaborations, mergers, and acquisitions.

Key Players

• Baxter International Inc.
• AstraZeneca
• AbbVie Inc.
• B. Braun Melsungen AG
• Fresenius SE & Co. KgaA
• Pfizer
• Hospira Inc.
• Aspen Pharmacare Holdings Limited
• Hikama Pharmaceuticals plc
• Abbott Laboratories

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. general anesthesia drugs market is set to witness steady growth, fueled by the increasing number of surgical procedures, advancements in anesthesia techniques, and an aging population with a rising prevalence of chronic diseases. The dominance of propofol and IV administration underscores the continued reliance on effective, reliable, and fast-acting anesthesia solutions. Additionally, the demand for orthopedic surgeries such as knee and hip replacements further strengthens market growth. Hospitals remain central to the market, given their role as primary providers of surgical care. With ongoing innovations and increasing healthcare demand, the market will continue to expand sustainably.